Lifecore Biomedical (LFCR) Stock
Medical materials company focused on hyaluronic acid. Here's the price, business snapshot, and what's worth knowing about Lifecore Biomedical in July 2026.
Lifecore Biomedical (LFCR) is a small-cap medical materials company focused on hyaluronic acid (HA) — a naturally occurring polymer used in ophthalmic, orthopaedic, aesthetic and regenerative-medicine applications. The company operates both product lines and contract development and manufacturing (CDMO) services, supplying customised HA solutions and sterile-fill manufacturing to medical-device and pharmaceutical customers. Investors should note Lifecore’s dual exposure to product demand and outsourced manufacturing trends: stable OEM partnerships can provide recurring revenue, while product innovation and regulatory approvals can unlock new markets. At a market cap of around $253m, the stock can be more volatile than larger peers and is sensitive to customer concentration, regulatory outcomes and capital-spend cycles. Evaluate Lifecore by reviewing revenue growth, gross margins, backlog, and cash flow, and consider industry risks. This is general educational information, not personalised investment advice; values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lifecore Biomedical's stock, expecting it to reach a higher price soon.
Financial Health
Lifecore Biomedical is maintaining steady cash flow and book value, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring LFCR
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: 23 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Dual Revenue Streams
Products and CDMO services give two potential growth levers, though performance can vary with customer demand and contract timing.
Manufacturing Edge
Specialist sterile-fill and HA expertise can attract OEM partners, but operations are capital and regulation intensive.
Market Exposure
Serves ophthalmic, orthopaedic and aesthetic markets with global opportunity, yet subject to regulatory and competitive headwinds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
